DSBA-like thioredoxin domain (PF01323), commonly found in the Gst kappa family, was uniquely presented in the TmGst17
Here is a quick snapshot of where each medication stands: Tirzepatide (brand names: Mounjaro for diabetes, Zepbound for weight loss): Greater average weight loss in trials, dual receptor mechanism, no FDA-approved cardiovascular outcomes indication as of 2026 Semaglutide (brand names: Ozempic for diabetes, Wegovy for weight loss): Slightly lower average weight loss, single receptor mechanism, FDA-approved for reducing major cardiovascular events in patients with established heart disease Administration: Both are once-weekly injections
As such, these dual agonists are often sold as sequels or improvements to mono agonists
First thing I noticed- my energy level naturally increased
Brown, The Johns Hopkins University School of Medicine, Baltimore, MD, USA Download the PDF here